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Abstract
Background: Malignant hyperthermia (MH) is a dominantly inherited skeletal muscle disorder that can cause a fatal 
hypermetabolic reaction to general anaesthetics. The primary locus of MH (MHS1 locus) in humans is linked to 
chromosome 19q13.1, the position of the gene encoding the ryanodine receptor skeletal muscle calcium release 
channel (RyR1).
Methods: In this study, an inexpensive allele-specific PCR (AS-PCR) assay was designed that allowed the relative 
quantification of the two RyR1 transcripts in heterozygous samples found to be susceptible to MH (MHS). Allele-
specific differences in RyR1 expression levels can provide insight into the observed variable penetrance and variations 
in MH phenotypes between individuals. The presence/absence of the H4833Y mutation in RYR1 transcripts was 
employed as a marker that allowed discrimination between the two alleles.
Results: In four skeletal muscle samples and two lymphoblastoid cell lines (LCLs) from different MHS patients, the wild 
type allele was found to be expressed at higher levels than the mutant RyR1 allele. For both LCLs, the ratios between 
the wild type and mutant RYR1 alleles did not change after different incubation times with actinomycin D. This 
suggests that there are no allele-specific differences in RyR1 mRNA stability, at least in these cells.
Conclusion: The data presented here revealed for the first time allele-specific differences in RYR1 mRNA expression 
levels in heterozygous MHS samples, and can at least in part contribute to the observed variable penetrance and 
variations in MH clinical phenotypes.
Background
Malignant hyperthermia (MH) [MIM no. 145600], first
described by Denborough and Lovell [1], is a dominantly
inherited skeletal muscle disorder that predisposes sus-
ceptible individuals to a potentially fatal reaction during
general anaesthesia [2]. Besides this toxic response to
anaesthetics, in rare circumstances MH may also be trig-
gered in susceptible individuals by severe exercise in hot
conditions, infections, neuroleptic drugs, or overheating
in infants [3]. The incidence of MH has been estimated to
be as high as 1:2000 [4]. The true genetic predisposition
of the condition is difficult to ascertain, since many ful-
minant MH reactions occur for the first time in patients
who have previously undergone uneventful anaesthesia
[5]. The clinical signs of an MH reaction are highly vari-
able and are caused by a hypermetabolic state with mus-
cle rigidity, metabolic acidosis, rhabdomyolysis,
tachycardia, and/or an increase in body temperature [6].
The primary locus of MH (MHS1 locus) in humans is
linked to chromosome 19q13.1, the position of the gene
encoding the ryanodine receptor skeletal muscle calcium
release channel (RyR1) [7,8]. Besides MH, the RYR1 gene
[MIM no. 180901, GenBank: NM_000540] is also linked
to congenital myopathies namely, central core disease
(CCD) [MIM no. 117000] and multi minicore disease
(MmD) [MIM no. 255320].
Due to the lack of clinical symptoms under normal con-
ditions and the heterogeneity of MH, the accepted 'gold
standard' diagnosis for susceptibility to MH (MHS) is by
in vitro contracture test (IVCT) [9]. Additionally, various
functional assays [10-13] and genetic tests [14] have been
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developed to aid in the understanding and diagnosis of
MH. Several studies reported discordance between MH
phenotypes and genotypes [15-18]. Different causative
MH mutations have been found to differentially affect
m u s c l e  c o n t r a c t i o n  i n  IV CT  a n d  C a 2+ release in func-
tional assays, respectively [19-21]. Girard et al. [20]
showed that halothane-induced changes in intracellular
calcium concentrations of skeletal muscle cells, is not
simply mutation specific. It was also found to be individ-
ual specific. These findings indicate that besides the spe-
cific mutation, a variety of other genetic and
environmental factors, such as muscle quality, mutation
penetrance, and variations in gene expression might also
play roles in the observed variations in MH phenotypes.
Polymorphisms and variations in gene expression pro-
vide the genetic basis for variation in populations. Several
recent studies revealed that allelic variations in gene
expression are common in the human genome even
among non-imprinted autosomal genes and can follow a
mendelian inheritance [22-24]. This suggests that other
mechanisms besides epigenetic phenomena can lead to
allelic variations and consequently may contribute to the
observed variations in MH phenotypes between individ-
uals.
This study aimed to determine if there are allele-spe-
cific differences in RYR1 messenger RNA (mRNA)
expression levels, in heterozygous MHS samples. The
causative H4833Y MH mutation was used as a marker to
allow discrimination between the two RYR1 transcripts
[11]. Measuring the expression of each of the two alleles
simultaneously in the one target tissue is optimal for
detecting cis-acting differences as each allele serves as an
internal control for the other. Any trans-acting effects of
environmental conditions that differentially influence
gene expression among samples should not interfere.
Plasmid constructs, representing the wild type and
mutant 4833 RYR1 alleles, were used for assay validation.
Four MHS skeletal muscle tissues were screened to deter-
mine if there were allele-specific differences in mRNA
expression levels between the wild type and mutant RyR1
alleles. Two lymphoblastoid cell lines (LCLs) derived
from blood of MHS individuals were used in mRNA sta-
bility assays to determine possible allelic-specific differ-
ences in RYR1 mRNA stabilities.
Methods
Patient samples
Four frozen MHS skeletal muscle tissues stored subse-
quent to biopsy for IVCT analysis and two Epstein-Barr
virus (EBV)-immortalized LCLs derived from blood of
MHS individuals carrying the causative H4833Y MH
mutation, were used after informed consent from partici-
pating subjects. Note that both skeletal muscle biopsies
and LCLs were not available from any single individual.
Thus, all four skeletal muscle biopsies and two LCLs were
obtained from six different MHS individuals. The study
was carried out after ethical approval was obtained from
the Whanganui-Manawatu human ethics committee.
In Vitro Contracture Testing
In vitro contracture testing of muscle biopsies was per-
formed according to the European Malignant Hyper-
thermia Group protocol [9].
Primer design
Two allele-specific forward primers (AS primers; AS1
and AS2) were designed with the 3' base of each primer
matching only the wild type or mutant H4833Y SNP,
respectively. To ensure allele specificity, a mismatch two
bases away from the 3'-end was added to each AS primer
[25]. Both AS1 and AS2 had melting temperatures close
to the annealing temperature (58°C). A common reverse
primer with a higher melting temperature (65°C) was
designed downstream of the polymorphic site and used
together with either AS1 or AS2 in separate reactions.
The AS-PCRs generated amplicons of 142 bp in size. The
hypoxanthine-guanine-phosphoribosyltransferase
(HPRT) [GenBank: M26434] gene was used as a refer-
ence, since it is expressed at lower levels as is RYR1, espe-
cially in LCLs. The primers for HPRT generated an
amplicon of 85 bp in size. All the primer pairs are listed in
Table 1 and span an intron to prevent genomic DNA
(gDNA) amplification.
Allele-specific PCR conditions
All assays were carried out in 96-well format in 10 μL vol-
umes and were performed using the following PCR
cycling conditions. The PCR was initiated with a 15 min.
hold at 95°C, followed by 45 cycles of 95°C for 10 s, 58°C
for 10 s, and 72°C for 6 s. A single fluorescence measure-
ment was conducted at the end of the 72°C extension seg-
ment. After heating the samples to 95°C for 5 s a melting
curve program (65-97°C, with a ramp rate of 0.11°C/s and
continuous fluorescence measurements), and finally a
cooling step to 40°C were conducted. PCR crossing
Table 1: Primer sequences
cDNA target Orientation Sequence (5'- > 3')
RYR1 Fw. (AS1) CCATCCTGTCCTCTGTCATCC
Fw. (AS2) CCATCCTGTCCTCTGTCATCT
Rev. (common) GGTTCATCCTCATCCTCGCTCTTG
HPRT Fw. TCCAAAGATGGTCAAGGTCGC
Rev. TTCAAATCCAACAAAGTCTGGCT
Additional mismatches in the AS-PCR primer sequences are 
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points (Ct values) were determined using the LightCycler
480 software. The reaction mixture for AS-PCR consisted
of 0.3 μM of each primer, and 1 × ABsolute™ QPCR SYBR®
Green Capillary Mix (ABgene).
Plasmid constructs
Engineered plasmids were used for assay validation and
created by cloning 409 bp complementary DNA (cDNA)
PCR fragments flanking the 4833 wild type and mutant
RYR1 sequences into pGEM-T Easy vectors (Promega).
The sequences of the cDNA forward and reverse primers
were 5'-ACCTGGGCTGGTATATGGTG-3' and 5'-
TGACGATGACGAAGAAG-3', respectively. DNA con-
centrations were estimated by A260. To assess primer
specificity both wild type and mutant constructs were
amplified with both AS1 and AS2. To test the possibility
of using the designed AS-PCR protocol for relative quan-
tification, four different ratios (1:1, 4:1, 3:1 & 1:2) of the
engineered wild type and mutant plasmid constructs
were mixed together in order to simulate heterozygotes.
Extraction of total RNA
Total RNA was extracted from ~100 mg frozen skeletal
muscle tissue or 5-10 × 106 cells using TRizol® Reagent
(Invitrogen) according to the manufacturer's instructions.
Before reverse transcription, total RNA was treated with
TURBO DNase (Ambion) according to the manufac-
turer's protocol.
Linearity of the reverse transcription
The reverse transcription is a crucial step in quantitative
analysis. To ensure that varying RNA amounts or RNA
dilutions did not affect the reverse transcription reaction,
the linearity of the reverse transcription reaction was
checked for all samples. DNase treated total RNA from
up to 1 μg for skeletal muscle and 2 μg for LCL was serial
diluted four or five times in 1:5 or 1:3 steps, respectively.
Due to the low RyR1 mRNA expression levels, dilutions
included MS2 RNA (Roche; final concentration 10 ng/μL)
in siliconized tubes to prevent binding to the sides of the
tubes and thus improve reproducibility. Equal volumes of
the serial diluted RNA were primed with Oligo(dT) and
subjected to cDNA synthesis using the SuperScript™ III
First-Strand Synthesis System for RT-PCR (Invitrogen)
according to the manufacturer's protocol. All dilutions
were amplified in triplicate with all three primer pairs
(AS1, AS2 and HPRT) and the linear relationships of
cDNA synthesis as a function of RNA content were deter-
mined by E = 10-1/slope. To verify the absence of contami-
nating cDNA or genomic DNA, reverse transcriptase was
omitted from the cDNA synthesis reaction.
PCR amplification efficiencies
PCR amplification efficiencies (E) of all three primers
pairs (AS1, AS2 and HPRT) were determined by making a
four or five times cDNA serial dilution in 1:5 or 1:3 steps,
respectively. In contrast to artificial or cloned standards,
these relative standards are more likely to have PCR effi-
ciencies identical to the unknown samples as they are
made from actual sample material. The dilutions were
made including MS2 RNA (Roche; final concentration 10
ng/μL) in siliconized tubes to prevent binding to the sides
of the tubes and thus improve reproducibility. The serial
diluted cDNAs were amplified in triplicate. PCR amplifi-
cation efficiencies were determined by constructing stan-
dard curves from the data of four individual experiments.
PCR amplification efficiencies were determined by E =
10-1/slope.
Establishment of lymphoblastoid cell lines
Peripheral mononuclear cells were isolated by Ficoll-
Hypaque (Amersham Biosciences) density gradient cen-
trifugation, from whole blood. The isolated mononuclear
cells were then transformed with Epstein-Barr virus [26].
Cells were grown in OptiMem medium (Invitrogen) sup-
plemented with 2% fetal calf serum (Invitrogen), and 100
U penicillin and streptomycin (Invitrogen), at 37°C, 5%
CO2. Cells were cultured up to a total of 1-3 × 107 cells
per 20 mL.
mRNA stability assays
An mRNA stability assay was designed and carried out
using LCLs to assess possible differences in mRNA stabil-
ities between the two RyR1 alleles in heterozygous sam-
ples. Following the assessment of the linearity of the
reverse transcription reactions and PCR amplification
efficiency determinations (as described above), mRNA
stability assays were conducted. After reaching the
desired densities the cells were split into four and incu-
bated with actinomycin D (Sigma-Aldrich) for 0, 2, 7 or
24 hours, at a final concentration of 5 μg/mL. Subse-
quently, total RNA was extracted and used for first-strand
cDNA synthesis. cDNA was generated each time from
the same amount of total RNA. The levels of all three tar-
gets (wild type RYR1: AS1, mutant RYR1: AS2 and HPRT)
were then measured in real-time PCR assays.
Results
Assay validations using plasmid constructs
Both wild type and mutant plasmids were amplified with
both AS1 and AS2 according to the conditions described
above. The amplification curves had identical steep sig-
moid curve shapes. Derivative melting curves generated
only a single peak (Tm ~88°C), indicating that no non-
specific products or primer-dimers were present. These
results were confirmed by 1% agarose gel electrophoresis.
Amplification of the wild type sequence by AS2 and
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delayed by at least 10 cycles, indicating appropriate speci-
ficities of the AS primers (data not shown).
To test the possibility of using the designed AS-PCR
protocol for relative quantification, different ratios of the
engineered wild type and mutant plasmid constructs
were mixed together in order to simulate heterozygotes.
Table 2 shows representative results as generated by a rel-
ative quantification experiment using plasmid constructs
that contained either the wild type or mutant RYR1
cDNA sequences. Each sample was amplified in tripli-
cate. The mean of the three Ct values was used to calcu-
late the allele frequencies of that allele by using Equation
1 [27].
ΔCt = (Ct of allele1 specific PCR - Ct of allele2 specific
PCR)
ΔΔCt = (Ct of allele1 specific PCR - Ct of allele2 spe-
cific PCR) - (ΔCt 1:1 ratio)
In order to correct for potential differences in amplifi-
cation efficiencies or plasmid concentrations the 1:1 ΔCt
value was subtracted from the 4:1, 3:1 and 2:1 ΔCt values.
The resulting 2ΔΔCt was used in Equation 1 to calculate
the relative allele frequencies (see Table 2). The observed
ratios matched the theoretical ratios with a maximum
error of < 2%, indicating the applicability and sensitivity
of the assay.
Relative quantification of RyR1 transcripts in MHS samples
The corrections described above for differences in ampli-
fication efficiency and DNA concentrations are not possi-
ble using sample cDNA. Therefore, amplification
efficiency determinations were conducted by making rel-
ative standards. Prior to amplification efficiency determi-
nations, the linearity of the reverse transcription reaction
was checked for all three targets. The amplification
curves had identical steep sigmoid curve shapes and
derivative melting curves generated only a single peak
(Tm ~88°C), indicating that no non-specific products or
primer-dimers were present. These results were con-
firmed by 1% agarose gel electrophoresis (data not
shown). Table 3 summarizes the results of testing all four
MHS skeletal muscle samples for linearity of reverse. The
results revealed that the reverse transcription reactions of
all RNA extracts were linear over the range used in this
study. Thus, the cDNA library generated can be expected
to be an appropriate representation of the mRNA popula-
tions in the samples.
PCR amplification efficiencies were calculated and
used for the determination of the relative RYR1 mRNA
allele frequencies. In order to correct for between-assay-
variability, PCR amplification efficiencies were deter-
Frequency of allele 1 2 1 1
Ct =+ () /
ΔΔ (1)
Table 2: Relative allele frequencies using engineered plasmid constructs
Ratio (WT:MT) Ct values Percentage (%)
Mean (n = 3) Stdev. ΔCt bΔΔCt Theor. Obs.
4:1 AS1 18.26 0.09 -3.35 -2.10 80.00 81.09
AS2 21.61 0.09 3.35 2.10 20.00 18.91
3:1 AS1 18.50 0.06 -2.72 -1.47 75.00 73.43
AS2 21.21 0.08 2.72 1.47 25.00 26.57
1:2 AS1 19.55 0.07 -0.21 1.04 33.33 32.67
AS2 19.76 0.04 0.21 -1.04 66.67 67.33
1:1 AS1 18.95 0.21 a-1.25 0.00 --
AS2 20.20 0.08 a1.25 0.00 --
Stdev. = Standard deviation, Theor. = theoretical values, Obs. = experimentally observes values. a The ΔCt value for the 1:1 ratio should be 
equal to zero. Any deviation indicates differences in amplification efficiencies or DNA concentrations of the added plasmid constructs. 
Therefore the 1:1 ΔCt values were subtracted from the ΔCt values leading to b ΔΔCt. This value was used in Equation 1 to calculate the relative 
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mined by constructing standard curves from the data of
four individual experiments. Figure 1 shows the standard
curves constructed for wild type RYR1 (AS1), mutant
RYR1 (AS2) and HPRT. As the error bars indicate, assay
variability was low. The "coefficient of variance" (CV%) of
the Ct values, between triplicates (intra-assay variation)
and between assays (inter-assay variation) was between
0.12% and 3% in each case. As could be expected, the
higher CVs were generally associated with the more
dilute samples. Only standard curves with slopes between
-3.1 to -3.6 and regression coefficients > 0.99 were con-
sidered to be reliable. These slopes correspond to amplifi-
cation efficiencies between 2.1 to 1.9, respectively. All
three targets that were screened in the four samples ful-
filled these requirements (see Table 4). The dilution series
for each of the four samples were chosen according to
their detected mRNA levels and the previously deter-
mined range of reverse transcription linearity. PCR
amplification efficiencies of samples, in which fewer tran-
scripts were detected, were determined by making 5 dilu-
Figure 1 Constructed standard curves for the determination of the PCR amplification efficiencies. Serial diluted 1:5 cDNA dilutions from the 
#1 MHS muscle biopsy. Each standard curve represents the pooled results of four individual experiments. Amplifications in each individual experiment 
were conducted in triplicate. Housekeeping gene; HRPT (triangles), wild type RYR1; AS1 (diamonds) and mutant RYR1; AS2 (squares). The error bars 
show the standard deviation. The regression coefficient was greater than 0.99 in all cases.
Table 3: Summary of the linearity of the reverse transcription reactions
Muscle sample # Amplification efficiencies and coefficient of correlation (E/R2)
AS1 AS2 HPRT
1 1.973/0.9957 1.913/0.9967 1.933/0.9990
2 2.074/0.9955 2.075/0.9956 2.032/0.9945
3 1.988/0.9986 1.873/0.9990 1.995/0.9923
4 1.976/0.9950 2.005/0.9908 2.107/0.9981Grievink and Stowell Orphanet Journal of Rare Diseases 2010, 5:10
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tions of 1:3 dilution steps instead 4 or 5 dilutions of 1:5
dilution steps.
Determining the relative allele frequencies
After assessing the linearity of the reverse transcription
reactions and determining the PCR amplification effi-
ciencies, the samples were screened to determine the rel-
ative quantities of the two RYR1 alleles in each of the four
samples. To confirm accuracy and reproducibility, the
allele frequencies were determined by performing three
independent experiments. Targets were amplified in trip-
licate within each experiment. Intra- and inter assay vari-
abilities as obtained by screening sample #1 are shown in
Table 5 and 6, respectively. As the results show, both
intra- and inter assay variations are low.
Several mathematical models are available for relative
quantification during real-time PCR. There are some
small differences between the individual models. Never-
theless, all relative quantification analyses are based on
the assumption that the concentration of the template
(e.g. cDNA) at a sample's crossing point is the same for
every sample containing the same target cDNA. The
model used in this study, is a rearranged version of the
efficiency calibrated mathematical method (see Equation
2) [28]. In this model, calculations are based on E and the
Ct values of an unknown "sample" versus a "calibrator".
The "target" is the nucleic acid of interest, while the "ref-
erence" is a nucleic acid that is found at constant copy
number in all samples and serves as an endogenous con-
trol. The "calibrator" is typically a sample with a stable
ratio of target-to-reference and can be used to normalize
all samples within a run, but in addition provides a con-
stant calibration point between several runs.
In this study the relative expression levels of all targets
were measured simultaneously in one target tissue. When
the two RYR1 alleles have identical mRNA expression lev-
els it can be assumed that their HPRT:AS1 and
HPRT:AS2 ratios will also be identical. Therefore, the two
can be compared as long as the amplification efficiencies
are corrected for. This eliminates the need for a calibra-
tor, and if preferred also the reference. Here, the reference
Normalized ratio =
(E ref) Ct sample
(E target) Ct sample
(E ref) Ct ca
÷
l librator
(E target) Ct calibrator
(2)
Table 5: Intra-assay variability of real-time AS-PCR when screening #1 (n = 3)
Experimental run # AS1 AS2 HPRT
Mean Ct Stdev CV% Mean Ct Stdev CV% Mean Ct Stdev CV%
1 23.66 0.13 0.54 24.08 0.10 0.40 27.21 0.12 0.42
2 23.65 0.06 0.06 24.13 0.02 0.09 27.16 0.05 0.19
3 23.53 0.27 1.14 24.08 0.11 0.11 27.09 0.12 0.43
Stdev. = Standard deviation, CV%= coefficient of variance.
Table 4: Mean PCR amplification efficiencies (n = 4)
Muscle sample # Amplification efficiencies and coefficient of correlation (E/R2)
AS1 AS2 HPRT
1 1.921/0.9993 1.941/0.9993 1.956/0.9987
2 2.068/0.9989 2.104/0.9995 1.999/0.9995
3 2.030/0.9989 2.045/0.9996 2.028/0.9988
4 2.011/0.9986 2.079/0.9993 1.976/0.9895
Dilutions series used for the determination of the PCR amplification efficiencies for each of the four MHS muscle tissues: 1; 1:5 dilution steps, 
2; 1:3 dilution steps, 3; 1:3 dilution steps, 4; 1:3 dilution steps.Grievink and Stowell Orphanet Journal of Rare Diseases 2010, 5:10
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was still used as an endogenous control. As a result, the
equation above was rearranged to Equation 3 and used
for the calculations.
Table 7 summarizes the results from the screens of the
four muscle samples, using the H4833Y causative MH
mutation as a marker . In all samples, expression of the
wild type RYR1 allele (AS1) was found to be higher than
the mutant RYR1 allele (AS2). In addition these values
seem to differ between individuals. When the RYR1
mRNA expression ratios are compared with the data
from the IVCT, no clear trend was detected.
mRNA stability assays
Allele-specific differences in mRNA expression levels can
have various causes (e.g. variations in mRNA transcrip-
tion, maturation or stability). Myoblasts containing the
H4833Y mutation were not available, thus immortalized
LCLs that were derived from blood of MHS (H4833Y)
individuals were used to assess the possibility that the
detected allelic variations could be caused by allele-spe-
cific differences in RYR1 mRNA stabilities.
As for the muscle tissues, the linearity of the reverse
transcription was determined for all three targets in
LCLs. Due to the lower RyR1 expression in LCLs, amplifi-
cation efficiencies were determined using five 1:3 dilution
steps. Table 8 depicts the results of the reverse transcrip-
tion linearity determinations in italics. As before, the
results revealed that the reverse transcription reactions of
all RNA extracts were linear over the range used in this
study. Subsequently, PCR amplification efficiencies were
determined from the data of four assays, and used for the
determination of the relative RYR1 mRNA allele frequen-
cies after actinomycin D incubations. The PCR amplifica-
tion efficiencies of all three targets for both LCLs are
underlined in Table 8.
mRNA stability assays were conducted by culturing
LCLs in the absence or presence of actinomycin D for 0,
2, 7 or 24 hours, respectively. The levels of all three tar-
gets (wild type RYR1; AS1, mutant RYR1; AS2 and HPRT)
were measured in by AS-PCR assays as described above.
To confirm accuracy and reproducibility, all targets were
measured in triplicate within each experiment (intra
assay variability). Inter assay variability was addressed by
Normalized ratio
(E HPRT) Ct HPRT
(E AS1) Ct AS1
(E HPRT) Ct HPRT
(E AS
=÷
2 2)Ct AS2
(3)
Table 7: Relative RYR1 allele ratios in muscle tissues (n = 3)
Normalized ratios Muscle sample
Mean ± stdev. #1 #2 #3 #4
Wild type RyR1 (CV%) 1.76 ± 0.08 (4.35%) 1.72 ± 0.27 (15.49%) 1.44 ± 0.14 (9.86%) 2.44 ± 0.40 (16.50%)
Mutant RyR1 1.00 1.00 1.00 1.00
IVCT data
Maximum caffeine tension (g) 3.8 2.0 1.9 2.9
Maximum halothane tension (g) 3.2 6.6 2.6 7.0
Stdev. = Standard deviation, CV%= coefficient of variance.
Table 6: Inter-assay variability of real-time AS-PCR when screening #1 (n = 3)
Target Mean Ct (n = 3) Stdev. CV%
AS1 23.61 0.07 0.31
AS2 24.10 0.03 0.14
HPRT 27.15 0.06 0.22
Stdev. = Standard deviation, CV%= coefficient of variance.Grievink and Stowell Orphanet Journal of Rare Diseases 2010, 5:10
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conducting each individual experiment three times. T o
assess assay reproducibility the complete mRNA stability
assays were repeated three times for both LCL #5 and #6.
Reproducibility between the three assays was high, as Ct
value CVs for both LCL #5 and #6, were < 3%. A clear
increase in Ct values was detected after actinomycin D
incubation after 24 hours, thus indicating a considerable
decrease in initial mRNA levels, due to the inhibition of
transcription see Additional file 1 and 2. For both LCLs
(#5 and #6) the RYR1 mRNA levels decreased by > 86%.
Note that the way the assay is conducted does not allow
reliable detection of mRNA transcription after just two
hours see Additional file 2. The mRNA levels of the
h o us e k ee p i n g  g e n e  i n  ea c h  L CL,  d ecr e as ed  b y  a t  l eas t
57%. The relative amount of mRNA in the t = 24 h sample
however, can be expected to be much higher compared to
the relative amount of mRNA in the t = 0 h sample. This
is because actinomycin D has a more pronounced effect
on RNA polymerase I (ribosomal RNA synthesis) than it
has on RNA polymerase II (mRNA synthesis) [29]. The
observed decrease in mRNA transcripts was believed to
be of an adequate range to allow for the detection of pos-
sible allele-specific differences between RYR1 mRNA sta-
bilities.
After confirming transcriptional inhibition, the nor-
malized ratios of the two RyR1 alleles were calculated,
using Equation 3. Table 9 depicts the results for LCLs #5
and #6. As in muscle, in both samples the wild type RYR1
allele (AS1) was found to be more abundant than the
mutant  RYR1 allele (AS2). For both LCLs the ratios
between the wild type and mutant RYR1 alleles did not
change significantly after different incubation times with
actinomycin D. Note that the ratios between the wild type
and mutant RYR1 mRNA expression levels differ between
LCLs.
Discussion
Allele-specific expression has been shown to be common
in the human genome even among non-imprinted auto-
somal genes and can play a major role in determining
phenotypic diversity [23]. Fluorescent dideoxy termina-
tors [30], matrix-assisted laser desorption/ionization
time-of-flight mass spectroscopy (MALDI-TOF MS) [31],
micro-arrays (Affymetrix HuSNP oligo arrays) and real-
time PCR using TaqMan probes [23] are several methods
that have been used for allele-specific expression analysis.
In this report, an assay was developed that combined
kinetic (real-time quantitative) PCR with allele-specific
amplification to determine the relative mRNA quantities
of the two RYR1 alleles in heterozygous MHS samples.
The causative H4833Y MH mutation present in the cod-
ing region of the RYR1 gene was used as a marker to dis-
tinguish between the two alleles. Unlike many other real-
time PCR methods, AS-PCR does not need expensive
fluorescently-labelled oligonucleotides. Instead SYBR
Green was used as an inexpensive generic fluorescent
DNA-binding dye.
Assay validations conducted using engineered plasmid
constructs revealed that both AS primers (AS1 and AS2)
were highly specific for either the wild type or mutant
RyR1 allele, respectively. A delay of at least 10 cycles was
observed upon non-specific binding. The possibility of
using the designed AS-PCR protocol for relative quantifi-
cation was tested by mixing the engineered wild type and
m u t a n t  p l a s m i d  c o n s t r u c t s  t o g e t h e r  i n  f o u r  d i f f e r e n t
ratios (1:1, 4:1, 3:1 and 1:2). The results indicated the
applicability and sensitivity of the AS-PCR assay as the
observed ratios matched the theoretical ratios with a
maximum error of < 2% (see Table 2).
Screening of the four MHS muscle samples revealed
allele-specific differences in RYR1 mRNA expression lev-
els (see Table 7). In all four samples the wild type (H4833)
Table 8: Linearity of the reverse transcription and PCR amplification efficiency determinations
LCL # Amplification efficiencies and coefficient of correlation (E/R2)
AS1 AS2 HPRT
5 1.882/0.9954 1.988/0.9953 2.059/0.9972
2.032/0.9975 2.039/0.9999 2.018/0.9997
6 2.051/0.9965 2.007/0.9998 2.034/0.9994
2.010/0.9993 2.014/0.9978 2.019/0.9997
Determinations of the linearity of the reverse transcription reactions are depicted in italics. PCR amplification efficiency determinations are 
underlined.Grievink and Stowell Orphanet Journal of Rare Diseases 2010, 5:10
http://www.ojrd.com/content/5/1/10
Page 9 of 11
allele was found to be expressed at higher levels than the
mutant RYR1 allele (Y4833). Note however, that it is not
necessarily the mutant RyR1 allele that is down-regu-
lated. It is possible that the cell compensates for the
defective RyR1 allele by increasing transcript levels of the
wild type RyR1 allele. In three (#1, #2 & # 4) out of four
samples the H4833Y MH mutation could be traced back
and was found to be inherited from the mother. The cal-
culated averages of the relative RyR1 allelic ratios of three
independent assays led to CV% values of < 17%, in all
cases. These slightly higher CV% values compared to Ct
value CV% are the result of the fact that the Ct values are
exponentially related to initial mRNA concentrations.
When the detected allelic ratios were compared with data
from the IVCT (see Table 7) no clear trend was detected.
This is not unexpected as the SR calcium release is a
finely regulated process that involves not only RyR1s.
Several other genetic and environmental factors can con-
tribute to the observed muscle contractions in the IVCT
(metabolic processes, enzyme activation, muscle compo-
sition, differences in gene expression). Furthermore, the
R y R 1  i s  c o m p r i s e d  o f  f o u r  i d e n t i c a l  s u b u n i t s .  I n  e a c h
tetramer, any of the individual RyR1 subunits can be
defective and thus contribute to the observed variations
in MH phenotypes. In addition only every other RyR1
tetramer is associated with a DHPR tetrad [32].
As H4833Y myoblasts were not available, LCLs were
used for mRNA stability assays using the transcription
inhibitor actinomycin D. LCLs are progressively being
u s e d  t o  a s s e s s  t h e  r o l e  o f  R y R 1  m u t a t i o n s  i n  c a l c i u m
release [11,13]. Possible allelic variations in RyR1 expres-
sion levels in LCLs can greatly affect the functional char-
acterization of potentially causative MH mutations. As
for skeletal muscle tissue, in each of the two LCLs (#5 and
#6) the wild type RyR1 allele (AS1) was found to be more
abundant than the mutant RyR1 allele (AS2; see Table 9).
In addition, the ratios between the wild type and mutant
RYR1 mRNA expression levels differ between LCLs. This
suggests that individual specific genetic and or environ-
mental factors also contribute to the relative expression
levels of wild type and mutant RyR1. In all cases, CV%
values of < 24% were obtained based on the calculated
averages of the relative RYR1 allelic ratios of three inde-
pendent experiments. These slightly higher CV% values
can be expected and are the result of the lower RYR1
mRNA expression levels in LCLs. For both LCL samples,
the ratios between the wild type and mutant RYR1 tran-
scripts did not change after different incubation times
with actinomycin D. This suggests that there are no
allele-specific differences in RyR1 mRNA stability, at least
in LCLs. Nevertheless, allelic variation has been reported
to be tissue specific [22,33]. Thus, the effect of allele-spe-
cific differences in RyR1 mRNA stabilities in H4833Y
MHS skeletal muscle tissues cannot be ruled out. Alter-
natively the observed allelic variation could be the result
of variations in mRNA transcription rates or mRNA mat-
uration.
The cause of the observed allelic variations is as yet
unknown. Nevertheless, the mechanism seems to be dis-
tinct from the one previously reported by Zhou, et al.
[34]. In that study, tissue-specific mono-allelic RYR1
expression was observed in a group of CCD patients with
recessive core myopathies. The transcribed allele which
was found to be paternally inherited carried a recessive
mutation. Additional analyses indicated that RYR1 allele
silencing was also tissue-specific and polymorphic during
early development and likely to be developmentally regu-
lated. It was hypothesized that genomic imprinting due to
long-term methylation effects could be responsible and
possibly also explain heterogeneity between MH pheno-
Table 9: Relative RYR1 allele ratios of LCLs after incubation with actinomycin D
Normalized ratios LCL #5 Actinomycin D incubation time (h) mean ± stdev.
027 2 4
Wild type RYR1 (CV%) 1.22 ± 0.25 (20.70%) 1.44 ± 0.24 (16.83%) 1.43 ± 0.22 (15.17%) 1.12 ± 0.07 (6.24%)
Mutant RYR1 1.00 1.00 1.00 1.00
Normalized ratios LCL #6
Wild type RYR1 (CV%) 1.86 ± 0.28 (15.21%) 1.82 ± 0.15 (8.14%) 1.86 ± 0.43 (23.38%) 1.67 ± 0.17 (10.05%)
Mutant RYR1 1.00 1.00 1.00 1.00
Stdev. = Standard deviation, CV%= coefficient of variance.Grievink and Stowell Orphanet Journal of Rare Diseases 2010, 5:10
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types [33,34]. Recently Robinson et al. investigated the
possibility of epigenetic RYR1 silencing and variable pen-
etrance of MH susceptibility. Out of 2113 transmissions,
it was found that affected (MHS or MH equivocal; MHE)
fathers had significantly fewer affected daughters than
affected sons or unaffected (MH negative; MHN) daugh-
ters. Nevertheless, no discrepancies were observed
between genotypes at the gDNA and cDNA level suggest-
ing the absence of mono-allelic RYR1 expression in MH
[35]. Note however that unlike the mono-allelic expres-
sion associated with e.g. genomic imprinting, the detec-
tion of possible minor allelic variations in gene expression
requires more quantitative detection methods.
Conclusion
The data presented here revealed for the first time allele-
specific differences in RyR1 mRNA expression levels in
heterozygous MHS samples. The detected allelic varia-
tion in RyR1 mRNA expression levels could at least in
part contribute to the observed variable penetrance and
variations in MH phenotypes [19-21]. Whether or not
these allele specific-differences translate through to the
protein levels remains to be elucidated.
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